

Clinical Policy: Teduglutide (Gattex)

Reference Number: IL.ERX.SPA.301

Effective Date: 06.01.21

Last Review Date: 05.21

Line of Business: Illinois Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

Description

Teduglutide (Gattex[®]) is a glucagon-like peptide-2 analog.

FDA Approved Indication(s)

Gattex is indicated for treatment of adult and pediatric patients 1 year of age and older with short bowel syndrome (SBS) who are dependent on parenteral support.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions[™] that Gattex is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Short Bowel Syndrome (must meet all):

1. Diagnosis of SBS;
2. Prescribed by or in consultation with a gastroenterologist;
3. Age \geq 1 year;
4. Dependent on parenteral nutrition or other intravenous support for \geq 12 months;
5. If age \geq 18 years, failure of a 4-week trial of somatropin (Genotropin[®] is preferred), unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for somatropin*
6. Dose does not exceed 0.05 mg/kg per day.

Approval duration: 12 months

B. Other diagnoses/indications

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy

A. Short Bowel Syndrome (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met all initial approval criteria;
2. Requirement for parenteral nutrition or other intravenous support has decreased since initiation of Gattex therapy;
3. If request is for a dose increase, new dose does not exceed 0.05 mg/kg per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.

Approval duration: Duration of request or 6 months (whichever is less); or

2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

SBS: short bowel syndrome

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria.

The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
somatropin (e.g., Genotropin®)	Refer to prescribing information (<i>dosing is individualized depending on nature and severity of disease, formulation, and patient response</i>)	Varies

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

None reported

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
SBS	0.05 mg/kg SC QD	0.05 mg/kg/day

VI. Product Availability

Single-use vial: 5 mg

VII. References

1. Gattex Prescribing Information. Lexington, MA: Shire-NPS Pharmaceuticals, Inc.; June 2019. Available at <http://www.gattex.com>. Accessed October 22, 2020.
2. Parrish CR, DiBaise JK. Managing the adult patient with short bowel syndrome. *Gastroenterology & Hepatology*. October 2017; 13(10): 600-608.
3. Seidner DL, Schwartz LK, Winkler MF, et al. Increased intestinal absorption in the era of teduglutide and its impact on management strategies in patients with short bowel syndrome – associated intestinal failure. *JPEN*. 2013; 37: 201-2011.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created.	04.20.21	05.21

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2021 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.